• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

COVID-19

NRx Pharmaceuticals touts Zyesami results, seeks EUA for treating COVID-19

June 1, 2021 By Sean Whooley

NRx NeuroRx_Logo

NRx Pharmaceuticals (NSDQ:NRXP) announced that it applied for FDA emergency use authorization based on a study of its Zyesami therapeutic. Radnor, Pa.-based NRx Pharmaceuticals, formerly NeuroRx, just last week completed a merger with SPAC Big Rock Partners Acquisition Corp. and went public, changing its name in the process. The company develops Zyesami, a synthetic form […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: coronavirus, COVID-19, NeuroRx, NRx

BD to build $200M facility in Spain for pre-filled drug delivery device manufacturing

May 18, 2021 By Sean Whooley

This is the logo of BD.

BD (NYSE:BDX) announced today that it will build a more than $200 million drug delivery device manufacturing facility in Spain. The approximately $201.5 million (€165 million) high-tech manufacturing facility in Zaragoza, Spain, is expected to create up to 600 jobs by 2030, according to a news release. In December, BD announced its plan to invest […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: BD, Becton Dickinson, coronavirus, COVID-19, COVID-19 vaccine

Intravacc touts preclinical, non-human results for COVID-19 nasal spray vaccine

April 7, 2021 By Sean Whooley

Intravacc

Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day one and […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials Tagged With: coronavirus, COVID-19, COVID-19 vaccine, Intravacc

Diomics, Bonne Santé Group enter strategic alliance

March 29, 2021 By Sean Whooley

Diomics Bonne Sante

Diomics and Bonne Santé Group announced today that they entered into a strategic alliance to develop a line of Diocare products. San Diego-based Diomics and Miami-based Bonne Santé Group, which operated through its Bonne Santé Natural Manufacturing division, entered the agreement in an effor tto develop, launch and distribute the Diocare products formulated to address […]

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Bonne Sante Group, coronavirus, COVID-19, Diomics

Oramed forms joint venture to develop oral COVID-19 vaccines with POD delivery tech

March 19, 2021 By Sean Whooley

Oramed

Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it is forming a joint venture to develop novel oral COVID-19 vaccines. New York-based Oramed entered into definitive agreements to form Oravax Medical, which is based on Oramed’s proprietary POD (protein oral delivery) technology and Premas Biotech’s novel vaccine technology, according to a news release. Oravax’s COVID-19 vaccine candidate […]

Filed Under: Business/Financial News, Discovery, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: coronavirus, COVID-19, COVID-19 vaccine, oramedpharmaceuticals

NeuroRX, TFF Pharmaceuticals enter feasibility agreement for Zyesami dry powder for COVID-19

March 10, 2021 By Sean Whooley

NeuroRx TFF Pharmaceuticals

NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: coronavirus, COVID-19, NeuroRx, TFF Pharmaceuticals

Baxter to make Moderna COVID-19 vaccine in US

March 9, 2021 By Chris Newmarker

Baxter Moderna

Baxter announced that its Baxter BioPharma Solutions business will make Moderna‘s COVID-19 vaccine at its fill/finish sterile manufacturing facilities in Bloomington, Ind. The plan — announced yesterday — is for Baxter to make 60–90 million doses of the Moderna vaccine in 2021. “We have seen a remarkable demonstration of scientific and health care expertise in […]

Filed Under: Contract Services, Featured Tagged With: Baxter, coronavirus, COVID-19, Moderna

Intranasal COVID-19 vaccines could be on the horizon

March 8, 2021 By Brian Buntz

Image courtesy of AltImmune

All of the COVID-19 vaccines authorized to date are delivered via intramuscular injection. But the intranasal vaccines that are now in development could lead to a more diverse vaccine landscape.  The company Altimmune (Gaithersburg, Md.) recently launched a Phase 1 clinical trial to test its single-dose adCOVID intranasal vaccine in 180 adult volunteers. Bharat Biotech […]

Filed Under: Clinical Trials, Otolaryngology Ear, Nose & Throat, Pediatrics, Pharmaceuticals, Research & Development, Respiratory Tagged With: COVID-19, intranasal, Intranasal COVID-19 vaccines

Pneumagen touts non-human results for intranasal drug treatment for COVID-19

March 8, 2021 By Sean Whooley

Pneumagen

Pneumagen announced today that study results show the effectiveness of its Neumifil intranasal drug in treating COVID-19. St. Andrews, Scotland-based Pneumagen’s Neumafil, a viral intranasal drug for protection against respiratory tract infections (RTIs), was used on a hamster model of COVID-19 infection and displayed effectiveness as it significantly reduced clinical signs and weight loss in […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, Pneumagen

Why COVID-19 could drive a surge in diabetes 

February 1, 2021 By Brian Buntz

diabetes devices

Diabetes was already an epidemic before the novel coronavirus struck. But some researchers now suspect that COVID-19 can trigger the condition. Approximately 14% of patients with severe COVID-19 develop the disease, according to a meta-analysis recently published in the journal Diabetes, Obesity and Metabolism. To arrive at that thesis, the researchers analyzed eight studies. Half of […]

Filed Under: Diabetes, Featured Tagged With: COVID-19, Diabetes, novel coronavirus

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS